Cranberry and urinary health is one of the oldest supplement stories there is. It’s also a useful case study, because three regulators looked at the same evidence and reached three different answers — and all three answers are still on shelves somewhere.
If you’ve ever wondered why one product says the berry helps and another says almost nothing, this is why.
The idea behind it
The old explanation was that cranberry made urine acidic, which made life hard for bacteria. That explanation is gone. Research in the 1980s found something different and disproved the acidity theory.
What replaced it is an anti-adhesion idea. Bacteria have to stick to the lining of the urinary tract before they can settle in and multiply. If they can’t stick, they get flushed out. Compounds in cranberry appear to interfere with that sticking.
The compounds are proanthocyanidins, usually shortened to PACs. They occur in grapes, apples, tea and dark chocolate too — but cranberry’s version has a structural difference, an A-type linkage, that the others mostly lack.
That’s the mechanism in one paragraph. It’s plausible, it’s specific, and it has held up. What happens next is where regulators part ways.
France, 2004: the first approval
France was the first country to approve a health claim for North American cranberry. The approval specified at least 36 mg of proanthocyanidins, and the permitted wording described helping reduce the adhesion of certain E. coli bacteria to urinary tract walls.
That number is worth remembering. If you’ve noticed 36 mg PAC printed on cranberry products, this 2004 French decision is where it comes from — not from a current international consensus.
It also predates the EU’s harmonised health claims framework, which arrived in 2006 and changed how such claims are handled across the bloc.
The United States, 2020: “qualified” is not “approved”
This is the part most people misread.
In July 2020 the FDA issued a letter of enforcement discretion covering certain cranberry products and reduced risk of recurrent UTI in healthy women. Read quickly, that sounds like approval. It’s closer to the opposite.
Ocean Spray had petitioned for an authorised health claim. The FDA reviewed it and concluded the evidence did not meet the “significant scientific agreement” standard required for one. The petition was then evaluated as a *qualified* health claim instead — a lower category that permits the claim only if the wording says the evidence is weak.
The permitted wording makes this explicit. For supplements: limited scientific evidence shows that consuming 500 mg daily of a cranberry dietary supplement may reduce recurrent UTI risk in healthy women who have had one. For juice beverages the required phrasing is stronger still — the evidence is described as limited and inconsistent.
So an American label carrying an FDA-linked cranberry claim is, in effect, telling you the FDA looked and found the evidence thin. The thresholds attached are at least 500 mg cranberry fruit powder for supplements, or at least 27% cranberry juice for beverages.
What this means when you compare products
Three jurisdictions, one berry.
| Jurisdiction | Position | Threshold specified |
| France (2004) | Health claim approved, anti-adhesion wording | ≥ 36 mg proanthocyanidins |
| EU (post-2006) | Harmonised framework; botanical claims largely unresolved | — |
| US (2020) | Qualified claim only; wording must state evidence is limited | ≥ 500 mg powder, or ≥ 27% juice |
[Table 1] How three regulators treated cranberry and urinary health · Source: Announcements from each regulatory authority[1][2][3]
None of these are wrong. They’re answers to slightly different questions, decided under different evidence standards, at different times. A product formulated for one market carries that market’s logic with it.
What the evidence reviews say about dose
Here’s the practical gap that cuts across all three.
Cochrane’s review of cranberry for preventing urinary tract infections makes three observations[4]. There is no established regimen for how much PAC to take. Cranberry products are not officially regulated by health authorities the way medicines are. And a suggested dose may not even appear on the package[4].
Set that beside the table above and the problem is visible. France specified 36 mg PAC. The US specified 500 mg of fruit powder. Those are different measures of different things — PAC content versus total powder weight — and a product can meet one while telling you nothing about the other.
If you want to compare two cranberry products meaningfully, the number to look for is PAC content, and many products don’t state it.
If you’re buying in Korea
Korea approves ingredients in advance and fixes the permitted wording, which we covered in an earlier post. That means the question here isn’t “what does the bottle claim” but “is this ingredient recognised, and for what.”
Two steps:
- **Check for the health functional food mark** (건강기능식품). Without it, the product is ordinary food and cannot carry a functional claim at all.
- **Look up the ingredient** on the MFDS food safety portal to see whether it’s recognised and what wording was approved[5]. Recognised ingredient lists change, so check at the time of purchase.
If you’re comparing a Korean product against one you used to buy at home, remember that the imported product’s claim reflects its own market’s rules. A US qualified health claim is not an approval, and it carries no standing in Korea.
Before you take it, or suggest it to someone
One thing has to be said plainly, because the anti-adhesion idea invites the wrong conclusion.
Cranberry does not treat an active infection. Prevention and treatment are separate questions, and this is a prevention discussion only. Burning, blood in urine, or fever means seeing a doctor, not reaching for a supplement.
A few other checks:
- If you take warfarin or another anticoagulant — an interaction has been discussed for this combination. Ask a clinician first.
- If you’ve had kidney stones — oxalate considerations apply. Worth raising.
- If infections keep recurring — the cause matters more than the product. After menopause, tissue changes can be part of the picture, and that changes the approach entirely.
- Juice products often contain added sugar, since the fruit is very tart on its own.
Closing
Cranberry is better understood than most things in this category. The mechanism is specific, it displaced an earlier wrong explanation, and the chemistry explains why this berry rather than another.
The confusion isn’t about the biology. It’s that “approved” means different things in different places, and the numbers printed on packages trace back to separate decisions made decades apart.
What surprised me most was the American case. A qualified health claim reads like endorsement and functions as a disclosure — the required wording exists precisely because the evidence didn’t clear the bar for a real approval. Knowing that changes how a label reads.
Next in this series: what changes in urogenital tissue after menopause, and why the approach differs from what works at 30.
At a Glance
- The old acidity explanation was disproved; the current one is anti-adhesion, via proanthocyanidins (PACs)
- Cranberry PACs carry an A-type linkage that grape, apple, tea and chocolate PACs mostly lack
- France, 2004 — first approval, specifying at least 36 mg PAC; this is where that number on packages comes from
- US, 2020 — the FDA found the evidence failed the standard for an authorised claim; only a *qualified* claim was permitted, and the wording must say the evidence is limited
- Thresholds differ in kind: 36 mg PAC versus 500 mg fruit powder measure different things
- Cochrane notes no established PAC regimen, and doses often aren’t on the package[4]
- Cranberry does not treat an active infection — prevention and treatment are separate questions
※ This article is for general information and does not replace medical advice, diagnosis or treatment. If you have burning on urination, blood in the urine or fever, please see a clinician rather than relying on a supplement. If you take anticoagulants, have a history of kidney stones, or experience recurrent infections, consult a clinician before starting any cranberry product.
References
- US FDA, “FDA Announces Qualified Health Claim for Certain Cranberry Products and Urinary Tract Infections” (21 July 2020), https://www.fda.gov/food/hfp-constituent-updates/fda-announces-qualified-health-claim-certain-cranberry-products-and-urinary-tract-infections
- NutraIngredients, “FDA outlines qualified health claim for cranberry juice and supplements” (France 2004 approval, 36 mg PAC), https://www.nutraingredients.com/Article/2020/07/22/fda-outlines-qualified-health-claim-for-cranberry-juice-and-supplements-for-urinary-tract-infections/
- EFSA, “Health claims (art. 13)” — status of botanical claims under the EU framework, https://www.efsa.europa.eu/en/topics/health-claims-art-13
- Williams G et al., “Cranberries for preventing urinary tract infections”, Cochrane Database of Systematic Reviews 2023, https://www.cochrane.org/ko/evidence/CD001321_cranberries-preventing-urinary-tract-infections
- Food Safety Korea (MFDS), ingredient and approved wording lookup, https://www.foodsafetykorea.go.kr/